Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742517 · ClinicalTrials.gov registry record · Phase 1
A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects
A Phase 1 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT04742517 is a Phase 1 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 102 participants.
The verdict
NCT04742517, a Phase 1 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of single ascending intravenous doses of ASP1128 in healthy adult male and female subjects and multiple ascending intravenous doses of ASP1128 in healthy adult male and female subjects and healthy elderly male and female subjects. This study will also evaluate the pharmacokinetics and the effect on the QT interval using Fridericia's correction formula (QTcF) in these subjects.
Interventions
- DRUG Placebo
- DRUG ASP1128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2018-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04742517
The ClinicalTrials.gov registry entry for NCT04742517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04742517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04742517 about?
NCT04742517 is a clinical study titled "A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects". The primary purpose of this study is to evaluate the safety and tolerability of single ascending intravenous doses of ASP1128 in healthy adult male and female subjects and multiple ascending intravenous doses of ASP1128 in healthy adult male and female subjects and healthy elderly male and female su...
What is the current status of trial NCT04742517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2017-11-20. Estimated completion is 2018-09-07.
What interventions are being tested in trial NCT04742517?
The interventions under investigation include: Placebo (DRUG), ASP1128 (DRUG).
Who is sponsoring clinical trial NCT04742517?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.